Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced the launch of ...

In environments where software influences real clinical decisions, rigor is not optional. It is the condition that makes ...

General purpose AI tools for science, such as Claude Science, promise to accelerate research. But which is right for you?

Lantern Pharma Inc. , a clinical-stage, AI-driven precision oncology company, today announced the launch of ZetaOmics, the computational-biology module of its multi-agentic AI co-scientist platform, ...

For researchers on the hunt for the genetic roots of disease, the cost of deep whole-genome sequencing makes it challenging ...

The rapid evolution of omic technologies such as spanning genomics, transcriptomics, and proteomics, is reshaping how we ...

OpenAI has launched its GPT-5.6 family, featuring Sol, Terra, and Luna, alongside a strategic desktop consolidation. The flagship Sol model nearly matches Anthropic's Claude Fable 5 on the AI Index ...

The BIOSECURE Act has moved from legislative possibility to operational reality. Enacted as part of the Fiscal Year 2026 National ...

Illumina dominates genomics sequencing with recurring growth, NovaSeq X catalysts, and improving margins/FCF. Click to know ...

CAMBRIDGE, Mass., July 9, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" or the "Company", HKEX: 3696), a generative artificial intelligence (AI)-driven clinical-stage biotech company, today ...

Insilico Medicine ("Insilico" or the "Company", HKEX: 3696), a generative artificial intelligence (AI)-driven clinical-stage biotech company, today delivered a positive profit alert for the six months ...